Session Information

  • WCLC 2022

    2022 World Conference on Lung Cancer

    Conference Program for 2022 the World Conference on Lung Cancer

    Presentation Date(s):  
    • August 6 - 9, 2022
    • Total Presentations: 2137

    All times listed are in Vienna, Austria Time, CEST (UTC+2:00)

    PL - Plenary
    IBS - Interactive Breakfast Session (in-person attendees only)
    ES - Education Session
    OA - Oral Session
    MA - Mini Oral Session
    P - Posters
    EP - ePosters
    WS - Workshops
    LA – Lectureship Awards
    IS - Industry Symposium

Filter Results:

Show Only CME Accredited Sessions

  • +

    EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      EP08.01-027 - Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON

      Presenter: Edward B. Garon

      • Abstract

      Loading...

  • +

    EP14.01 - Small Cell Lung Cancer and Neuro-endocrine Tumors - Informing ES-SCLC

    • 09:45 - 18:00
    • 8/07/2022
    • Location: Exhibit Hall - Hall B
    • Not for CME Credit
    • Type: E-Poster
    • Track: Small Cell Lung Cancer and Neuro-endocrine Tumors - Informing ES-SCLC
    • +

      EP14.01-015 - IMforte: A Phase III Study of Lurbinectedin and Atezolizumab Versus Atezolizumab as Maintenance Therapy in ES-SCLC

      Presenter: Luis Paz-Ares

      • Abstract

      Loading...

  • +

    OA06 - Impact of COVID-19 on Cancer Management and Protection from Vaccines

    • 11:00 - 12:10
    • 8/08/2022
    • Location: Lehar 1
    • Not for CME Credit
    • Type: Oral
    • Track: Management of Lung Cancer in the Era of COVID-19
    • +

      OA06.06 - Impact of Systemic Anti-cancer Treatments on Outcomes of COVID-19 in Patients with Thoracic Cancers: CCC19 Registry Analysis

      11:32 - 11:42  |  Presenter: Amit Kulkarni

      • Abstract

      Loading...

  • +

    OA12 - Novel and Combination Strategies for SCLC

    • 16:00 - 17:00
    • 8/08/2022
    • Location: Hall C8
    • Not for CME Credit
    • Type: Oral
    • Track: Small Cell Lung Cancer and Neuro-Endocrine Tumors
    • +

      OA12.06 - First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results

      16:32 - 16:42  |  Presenter: Charles M Rudin

      • Abstract

      Loading...

  • +

    IS24 - Industry Sponsored Symposium by MSD: New Frontiers in the Management of NSCLC

    • 18:00 - 19:00
    • 8/08/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Industry Symposium
    • Track: N/A
    • +

      Session Moderator

      18:00 - 18:00  |  Presenter: Solange Peters

      • Abstract

      Loading...

    • +

      IS24.01 - Welcome and Introduction

      18:00 - 18:05  |  Presenter: Solange Peters

      • Abstract

      Loading...

    • +

      IS24.02 - Evolving Treatment Landscape in Metastatic NSCLC

      18:05 - 18:15  |  Presenter: Solange Peters

      • Abstract

      Loading...

    • +

      IS24.06 - Closing Remarks

      19:00 - 19:00  |  Presenter: Solange Peters

      • Abstract

      Loading...

  • +

    IBS17 - Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings? (Ticketed Session) (In-person Access Only)

    • 07:30 - 08:15
    • 8/09/2022
    • Location: Lehar 3
    • IASLC CME Accredited
    • Type: Interactive Breakfast Session
    • Track: Tumor Biology and Biomarkers
    • +

      IBS17.02 - Interactive Debate: Predictive Biomarkers for Immunotherapy: Which Biomarker to Use across Histologies and Clinical Settings?

      07:45 - 08:00  |  Presenter: Solange Peters

      • Abstract

      Loading...

  • +

    OA15 - Patient Selection in Advanced NSCLC Immunotherapy

    • 14:30 - 15:30
    • 8/09/2022
    • Location: Hall C7
    • Not for CME Credit
    • Type: Oral
    • Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
    • +

      OA15.04 - Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC

      14:42 - 14:52  |  Presenter: Solange Peters

      • Abstract

      Loading...